Masimo Co. (NASDAQ:MASI) COO Anand Sampath sold 30,000 shares of the stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $110.00, for a total transaction of $3,300,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Masimo stock traded up $0.96 during midday trading on Friday, hitting $110.42. 463,404 shares of the company’s stock were exchanged, compared to its average volume of 499,700. Masimo Co. has a 12 month low of $80.69 and a 12 month high of $126.89. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 45.07, a PEG ratio of 2.41 and a beta of 1.11.
Masimo (NASDAQ:MASI) last issued its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.02. Masimo had a net margin of 17.08% and a return on equity of 20.29%. The company had revenue of $210.58 million for the quarter, compared to analysts’ expectations of $207.62 million. During the same period in the prior year, the business earned $0.56 EPS. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. Research analysts predict that Masimo Co. will post 2.92 earnings per share for the current year.
MASI has been the topic of several recent research reports. Stifel Nicolaus increased their target price on shares of Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. BidaskClub cut shares of Masimo from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies increased their target price on shares of Masimo to $120.00 and gave the stock a “neutral” rating in a report on Thursday, November 1st. Finally, UBS Group initiated coverage on shares of Masimo in a report on Tuesday. They set a “buy” rating and a $137.00 target price on the stock. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $119.00.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2018/12/01/masimo-co-masi-coo-anand-sampath-sells-30000-shares.html.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Story: Understanding each part of a balance sheet
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.